

# Inherent Bias in Electronic Health Records: A Scoping Review of Sources of Bias

ORIEL PERETS, Ben-Gurion University of the Negev, Israel

EMANUELA STAGNO, University of Sussex Business School, UK

EYAL BEN YEHUDA, Ben-Gurion University of the Negev, Israel

MEGAN MCNICHOL, Beth Israel Deaconess Medical Center, USA

LEO ANTHONY CELI, Harvard–MIT Division of Health Sciences & Technology, USA

NADAV RAPPOPORT, Ben-Gurion University of the Negev, Israel, Senior Author

MATILDA DOROTIC, BI Norwegian Business School, Norway, Senior Author

## 1 ABSTRACT

### 1.1 Objectives

Biases inherent in electronic health records (EHRs), and therefore in medical artificial intelligence (AI) models may significantly exacerbate health inequities and challenge the adoption of ethical and responsible AI in healthcare. Biases arise from multiple sources, some of which are not as documented in the literature. Biases are encoded in how the data has been collected and labeled, by implicit and unconscious biases of clinicians, or by the tools used for data processing. These biases and their encoding in healthcare records undermine the reliability of such data and bias clinical judgments and medical outcomes. Moreover, when healthcare records are used to build data-driven solutions, the biases are further exacerbated, resulting in systems that perpetuate biases and induce healthcare disparities. This literature scoping review aims to categorize the main sources of biases inherent in EHRs.

### 1.2 Methods

We queried PubMed and Web of Science on January 19th, 2023, for peer-reviewed sources in English, published between 2016 and 2023, using the PRISMA approach to stepwise scoping of the literature. To select the papers that empirically analyze bias in EHR, from the initial yield of 430 papers, 27 duplicates were removed, and 403 studies were screened for eligibility. 196 articles were removed after the title and abstract screening, and 96 articles were excluded after the full-text review resulting in a final selection of 116 articles.

### 1.3 Results

Systematic categorizations of diverse sources of bias are scarce in the literature, while the effects of separate studies are often convoluted and methodologically contestable. Our categorization of published empirical evidence identified the six main sources of bias: a) bias arising from past *clinical trials*; b) *data-related biases* arising from missing, incomplete information or poor labeling of

Authors' addresses: [Oriël Perets](mailto:orielp@post.bgu.ac.il), [orielp@post.bgu.ac.il](mailto:orielp@post.bgu.ac.il), Ben-Gurion University of the Negev, P.O. Box 1212, Beer Sheva, Israel, 43017-6221; [Emanuela Stagno](mailto:emmanuel.stagno@sussex.ac.uk), University of Sussex Business School, Sussex, UK; [Eyal Ben Yehuda](mailto:eyalbenyehuda@gmail.com), Ben-Gurion University of the Negev, Beer Sheva, Israel; [Megan McNichol](mailto:megan.mcnichol@bidmc.harvard.edu), Beth Israel Deaconess Medical Center, Boston, MA, USA; [Leo Anthony Celi](mailto:leo@hms.harvard.edu), Harvard–MIT Division of Health Sciences & Technology, Boston, MA, USA; [Nadav Rappoport](mailto:nadavrap@bgu.ac.il), [nadavrap@bgu.ac.il](mailto:nadavrap@bgu.ac.il), Ben-Gurion University of the Negev, Beer Sheva, Israel, Senior Author; [Matilda Dorotic](mailto:matilda.dorotic@bi.no), BI Norwegian Business School, Oslo, Norway, Senior Author.

Permission to make digital or hard copies of all or part of this work for personal or classroom use is granted without fee provided that copies are not made or distributed for profit or commercial advantage and that copies bear this notice and the full citation on the first page. Copyrights for components of this work owned by others than the author(s) must be honored. Abstracting with credit is permitted. To copy otherwise, or republish, to post on servers or to redistribute to lists, requires prior specific permission and/or a fee. Request permissions from [permissions@acm.org](mailto:permissions@acm.org).

© 2024 Copyright held by the owner/author(s). Publication rights licensed to ACM.

Manuscript submitted to ACM

Manuscript submitted to ACM

1

53 data; *human-related bias* induced by c) implicit clinician bias, d) referral and admission bias; e) diagnosis or risk disparities bias and  
54 finally, (f) biases in machinery and algorithms.

#### 56 1.4 Conclusions

57 Machine learning and data-driven solutions can potentially transform healthcare delivery, but not without limitations. The core  
58 inputs in the systems (data and human factors) currently contain several sources of bias that are poorly documented and analyzed  
59 for remedies. The current evidence heavily focuses on data-related biases, while other sources are less often analyzed or anecdotal.  
60 However, these different sources of biases add to one another exponentially. Therefore, to understand the issues holistically we need  
61 to explore these diverse sources of bias. While racial biases in EHR have been often documented, other sources of biases have been  
62 less frequently investigated and documented (e.g. gender-related biases, sexual orientation discrimination, socially induced biases,  
63 and implicit, often unconscious, human-related cognitive biases). Moreover, some existing studies lack causal evidence, illustrating  
64 the different prevalences of disease across groups, which does not *per se* prove the causality. Our review shows that data-, human-  
65 and machine biases are prevalent in healthcare and they significantly impact healthcare outcomes and judgments and exacerbate  
66 disparities and differential treatment. Understanding how diverse biases affect AI systems and recommendations is critical. We suggest  
67 that researchers and medical personnel should develop safeguards and adopt data-driven solutions with a “bias-in-mind” approach.  
68 More empirical evidence is needed to tease out the effects of different sources of bias on health outcomes.

71 CCS Concepts: • **Computing methodologies** → **Machine learning**; **Machine learning approaches**; • **Applied computing** →  
72 **Health care information systems**; **Health informatics**; • **Social and professional topics** → **Personal health records**; **Medical**  
73 **records**.

75 Additional Key Words and Phrases: Electronic Health Records (EHRs), AI Bias, Machine Learning (ML), Clinical Trial, Medical  
76 Machinery, Human Bias, Implicit bias

#### 78 ACM Reference Format:

79 Oriel Perets, Emanuela Stagno, Eyal Ben Yehuda, Megan McNichol, Leo Anthony Celi, Nadav Rappoport, and Matilda Dorotic. 2024.  
80 Inherent Bias in Electronic Health Records: A Scoping Review of Sources of Bias. 1, 1 (April 2024), 24 pages. <https://doi.org/XXXXXXXX>.  
81 XXXXXXXX

## 84 2 INTRODUCTION

85 In the United States, The Health Information Technology for Economic and Clinical Health Act [66], enacted in 2009,  
86 fueled innovation programs that promoted the use of EHRs in creating artificial intelligence (AI) solutions. Globally,  
87 similar programs have promoted the use of EHRs in algorithms and systems that aim to improve the operational and  
88 administrative efficiency of healthcare systems. The exponential growth of patient data has opened up promising  
89 avenues for enhancing how physicians take care of their patients. Only in 2020, around 2.31 exabytes of new data  
90 were generated in healthcare [124]. To improve efficiency in analyzing this vast amount of information and deriving  
91 actionable insights to enhance decision-making, AI is used in multiple domains, including healthcare. AI systems  
92 are trained on data collected in medical facilities, mainly EHRs which contain patients’ medical history. EHRs are  
93 typically maintained by a health provider over time and may include all of the key administrative clinical data relevant  
94 to that person’s care, including demographics, progress notes, problems, medications, vital signs, past medical history,  
95 immunizations, laboratory data, and radiology reports [69].

96 The training of AI on EHRs creates opportunities for improved efficiency in analyzing the vast amount of health  
97 data and for deriving actionable insights to enhance decision-making at a significantly lower cost. The benefits include  
98 early prediction of disease risks, forecasting prognosis and development of disease, identifying to-human-eye-hidden  
99 data patterns, and providing personalized treatment recommendations for optimizing the delivery of treatment to large  
100  
101  
102  
103

105 amounts of patients (which would not be feasible otherwise due to the limited availability of human resources). For  
106 example, AI can significantly more accurately than human experts screen and detect the risk of dementia [13] and  
107 improve the prediction of long-term recurrence risks for patients with ischemic cerebrovascular events after discharge  
108 from the hospital [143]. Moreover, the adoption of AI solutions to classify skin lesions using images is superior to  
109 humans in the challenging task of diagnosing the fine-grained variability in the appearance of skin lesions [41]. AI  
110 solutions can also be used to diagnose diseases such as diabetic retinopathy in parts of the world where there are too  
111 few ophthalmologists to read the fundus photographs and to follow up with each diabetic patient [144].  
112

113 However, while powerful, AI solutions are only as good at making judgments as the data they are based on and  
114 humans that interpret and oversee its results [120]. Consequently, models based on the evaluation of EHRs can be  
115 subject to different types of biases [16]. In this paper, we define the biases inherent in EHRs or medical AI as the presence  
116 of systematic errors, unintentional prejudices, and inaccuracies in medical data that can affect the quality and fairness of  
117 healthcare delivery and decision-making [54]. EHR may hold inherent biases that occur through how data is collected,  
118 analyzed, or used. These inherent biases may be hidden in the data as they have many different sources, which may  
119 be hard to identify or correct, but they are likely to exacerbate the biases that the users of such data make (AI, health  
120 systems, or health professionals). For example, EHRs can be subject to biases arising from collecting, reporting, labeling,  
121 or designing EHRs, biases arising from implicit, unconscious stereotypes that healthcare professionals or algorithm  
122 engineers have as humans [45] or inherent biases in algorithms and machine learning (ML) models. These diverse  
123 biases can produce systematic errors in the data used to train AI solutions, which in turn spread through the system  
124 and exacerbate biased decision-making of healthcare professionals. As such, these biases limit reliability, perpetuate  
125 disparities, and increase health inequities when developing data-driven solutions from biased EHRs to treat patients.  
126 Nevertheless, it is unclear from which sources biases arise and how different types of biases specifically affect healthcare  
127 outcomes. Finding potential remedies for the biases requires a deep understanding of its causes, which currently only  
128 surfaces in the literature [60].  
129

130 The outcomes of biases are potentially grave. For example, disease misclassification occurs as a consequence of  
131 bias hindering machine learning models developed on EHRs [94]. A potential source of bias emerges from disparities  
132 in diagnosis and prognosis for patients with different demographic or societal/environmental attributes. In a study  
133 of all reported trials supporting FDA oncology drug approvals between 2008 and 2018, Black and Hispanic races are  
134 consistently underrepresented compared with their burden of cancer incidence [87]. Previous research has shown  
135 disparities in diagnosis between patients with different types of cancers [57] or differences in risk of HIV between Black  
136 and White men when accounting for confounding variables [57]. The use of such data to build models that predict the  
137 health needs based on the existing patterns in the EHRs would be consequently skewed in favor of overrepresented  
138 rather than underrepresented populations [105].  
139

140 On top of more known sources of inherent bias in data, the literature also mentions less investigated sources such as  
141 the biases connected to the usage of medical devices/algorithms or implicit (and often unconscious) human biases when  
142 treating patients with different demographic characteristics [45]. These biases are sometimes perceived to originate from  
143 the measurement error of the machinery, but at other times they are attributed rather to the differences in diagnoses or  
144 prognoses those devices create for patients with different demographic attributes. For example, significant variability  
145 was found in measurements of oxygen saturation levels for a given SpO<sub>2</sub> level in Black patients relative to Hispanic,  
146 Asian, and White patients due to differences in how devices function on patients with different skin characteristics  
147 [140]. Although patients with or without hidden hypoxemia had similar clinical and demographic attributes, those with  
148 hidden hypoxemia had more comorbidities [68]. On the other hand, some studies showed that biased outcomes may  
149

157 also arise due to implicit, unconscious human biases of healthcare professionals (due to stereotypes, prejudice, or other  
158 unconscious cognitive biases), which consequently negatively affect the quality of care [45]. Such biases may affect  
159 the referrals to treatment. For example, previous studies have shown a systematically lower percentage of preventive  
160 cervical cancer screening for lesbian/gay patients than for bisexual and heterosexual patients across five US federally  
161 qualified health centers [60].

163 From the current findings, it is unclear how biases differ across diverse sources, what their idiosyncrasies are, and  
164 how to address these various biases. It remains unclear what exactly causes various biases and how they affect the  
165 decision-making of health professionals and AI systems. It does not help that the terminology related to biases is vast  
166 and varied such that different types of biases are confused in terminology, while biases coming from different sources  
167 are treated as synonyms, which further increases confusion. The identification of biases in the data used to train AI  
168 is a key pillar for constructing fair and responsible AI to be used in decision-making. Therefore, identification of the  
169 sources of biases is an important step in developing solutions to address these biases. Indeed, in health care, growing  
170 attention is given to understanding responsible approaches to the development, implementation, management, and  
171 governance of AI [120].

174 This project aims to categorize the main sources of inherent biases in EHRs documented in the existing literature. In  
175 particular, the purpose of this scoping review is to answer the following questions:

- 177 (1) *What is the extent and nature of inherent bias in electronic health records collected in medical facilities?*  
178 (2) *What are the prominent sources of bias in EHRs?*  
179

180 A scoping review methodology was used [129] for a comprehensive overview of the existing literature on these topics.

### 182 3 METHOD

183 This review was conducted and reported following the Preferred Reporting Items for Systematic Reviews and Meta-  
184 analyses extension for Scoping Reviews (PRISMA-ScR) [120].

#### 187 3.1 Protocol Registration

188 A protocol for this scoping review has been registered with OSF. The protocol is available at: <https://osf.io/skdm7>

#### 191 3.2 Eligibility Criteria

192 The eligibility criteria for the selection of papers included in our systematic review of the literature were as follows: (1)  
193 articles must explore some type of bias that may affect EHRs, (2) be written in English, (3) published between 2016  
194 and 2023 (since the major investigative work on AI biases started in 2016), (4) published in peer-reviewed journals,  
195 and (5) include empirical evidence of some form of bias. We included most study designs, from experimental and  
196 quasi-experimental study designs to randomized controlled trials, non-randomized controlled trials, before and after  
197 studies, interrupted time-series studies, analytical observational studies, and descriptive observational studies. We  
198 excluded opinion pieces, conceptual papers, and medical case studies as these can't indicate a larger-scale phenomenon  
199 or statistically show the existence of bias. To narrow the search and identify the sources of bias in classic medicine (e.g.,  
200 medical care administered in a hospital or medical facility) articles were also excluded if they focused on a subject out  
201 of scope for this review, including psychiatry, psychology, dentistry, veterinary, and medical education.

### 3.3 Search Strategy

We applied the search strategy to two large databases, PubMed [22] and Web of Science, as their scope and coverage of the topics at hand are relevant and extensive. The initial query consisted of several key subject terms including and adjacent to: “Bias” in combination with terms such as “electronic health record,” “EHR,” “healthcare provider,” “clinical dataset,” “disparities,” “racial,” “ethnic,” “implicit,” “gender,” “unconscious,” “socioeconomic,” “machine” etc. The queries aimed to cover diverse sources of bias that may be inherent in EHRs and the medical field. The final search strings used for each database are presented in Appendix A. These queries yielded roughly 8,000 search results. Hence, we iteratively added conjunctions and exclusions of topics out of scope for this review. After the first analysis of the title and abstract, articles discussing disparities in medical education, workplace or wage disparities of medical practitioners, and gender-related bias in surgical residency were excluded. We narrowed the search strategy years to 2016-2023 to decrease the number of results while providing a time-relevant overview of the literature, justified by the increased interest and resources invested in equitable care and fairness in machine learning in recent years [55]. In the next stages, while reviewing selected studies, we used the snowball sampling technique to identify relevant studies for our analysis that were referenced in included articles but which we missed in our initial search.

### 3.4 Study/Source of Evidence Selection

Based on the database query from the previous section, 410 articles were retrieved and uploaded to the “Covidence” systematic review management platform for the review process. Key sources were identified through discussion, from which minimal cross-referencing was conducted by the authors, resulting in 20 additional sources manually added to Covidence. To provide unified criteria for the inclusion of sources, based on the readings and discussion among authors in our interdisciplinary team, we have defined broad categories of bias as those related to data, humans, and algorithms or machinery. Of the 430 sources included for review, 27 duplicates were identified and removed, and 403 studies were screened for eligibility in two stages. First, titles and abstracts were screened for further analysis, with the main criteria being that the study analyzes some form of inherent bias (as identified earlier) in a medical context. This phase excluded 191 articles (Figure 1). Next, a full-text review was conducted on the remaining 212 articles. Sources were excluded based on the following criteria: 1. The study was not peer-reviewed; 2. Editorials, conceptual pieces without data, or a qualitative study design (21); 3. The topic was irrelevant to this study (6); 4. The study does not illustrate an inherent bias (24); and 5. The study shows prevalence or differences in groups of patients but it does not provide evidence of bias (45). All excluded papers were labeled by at least two reviewers, and any conflicts were discussed between reviewers and resolved by a third reviewer. This phase resulted in the exclusion of 96 articles. We note that the main reason why relatively many of the initial hits were excluded refers to the fact that articles did not test empirically for bias. This points out the deficit of empirical studies, despite the wide discussion of these issues. Eventually, 116 articles were included for the scoping review. The full inclusion process is displayed in Figure 1.

### 3.5 Data Extraction/Data Items

An analysis of the articles included after applying the eligibility criteria and conducting a full-text review revealed that they could be grouped into six categories of sources of bias. These sources were further categorized into primary and secondary bias categories, and specific details about the bias characteristics, context, study methods, and findings relevant to the review question were extracted. This process was carried out independently by two or more reviewers and is presented in the synthesis of the results section.

261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312




Fig. 1. PRISMA exclusion flowchart: the flow chart describes the number of filtered articles and the reasons for exclusion

## 4 FINDINGS

### 4.1 Important terminology issues identified in the studies

The above analysis of studies offered important insights. We found that the terminology of the phenomena varies across disciplines, areas, and studies. While the term "inherent bias" is prominent in medicine, "machine bias" and its synonyms are used in engineering and computer science literature, and "systemic, algorithmic, or AI bias" are terms prominently used in social science literature. This indicates the need for a careful and broad selection of keywords and mechanisms when reviewing the phenomena.

### 4.2 Important methodological issues identified in the studies

The most prominent methodological issue we found across studies is the problem that many studies, that use the term bias or indicate they study biases in healthcare, often do not employ the methodological approaches suitable for testing the causal effects that would show the impact or presence of a bias. As indicated above, most excluded studies (and related discussions among reviewers) concern studies showing the prevalence of a condition in different populations or other differences between groups. While biases certainly may arise from these differences, they do not unequivocally prove the bias itself or the cause of the bias. Merely showing differences in two populations (e.g., group A being more prone to an illness or less willing to receive treatment relative to group B) does not directly confirm inherent bias in EHRs or machinery, as there is no link established between the effect and bias and its outcomes. We illustrate the issue with a famous example that showed using the overall (past) spending on healthcare as a proxy for predicting (future) healthcare needs/likelihood to develop complications results in machine bias that prioritizes treatment for affluent White patients at the cost of less represented Black patients, who were less represented in the data due to their lower utilization of the healthcare system [105]. Showing the resulting causal effect of using such an unrepresentative proxy which would lead to a biased algorithm, that would in turn give biased predictions for underrepresented groups, is an example of proving inherent bias.

## 5 SOURCES OF BIAS IN EHRs

Through an in-depth analysis of the included 116 papers, co-authors of this study classified the papers into six main sources of bias: (a) clinical trial-induced biases, (b) missing, incomplete, or poor labeling biases; (c) implicit clinician biases, (d) referral and admission biases, (e) diagnosis, prognosis or risk disparities biases, and (f) medical machinery (AI) biases. It is noteworthy to point out that diverse other names exist for these types of bias, which we reference in the text when discussing those biases. The prevalence of each type of bias among the selected 116 papers is presented in Table 1. We note that these different sources of biases are not mutually exclusive; they may overlap, lead to one another, or be otherwise interrelated. We have used these six categories holistically to show that biases differ in their sources, and these differences should be considered, both by researchers and practitioners.

Table 1. Types of bias and number of detected and screened publications.

Type	Form of Bias	n	Prevalence	References
Data-related Biases	Clinical Trial Induced Bias	5	4%	[12, 19, 40, 87, 109]
	Missing, Incomplete, Poor Logging of Information	14	12%	[3, 21, 31, 39, 54, 67, 73, 81, 84, 100, 103, 104, 108, 119, 126]
Human-induced Biases	Implicit Clinician Bias	19	16%	[7, 24, 29, 35, 36, 43, 45, 75, 76, 86, 110, 112, 122, 130, 131]
	Referral and Admission Bias	41	35%	[6, 10, 15, 18, 32–34, 37, 42, 43, 46, 47, 52, 59, 60, 64, 70, 72, 77–80, 82, 85, 89–93, 97, 99, 107, 113, 115, 118, 121, 123, 138, 139, 141, 142, 145]
	Diagnosis, Prognosis or Risk Disparities Bias	30	26%	[1, 8, 20, 23, 25, 30, 38, 49–51, 57, 61, 62, 65, 74, 83, 88, 95, 100, 117, 125, 132, 134, 135, 137]
Machine Bias	Medical Machinery Bias	9	8%	[4, 9, 11, 68, 106, 116, 127, 133]

### 5.1 Clinical trial-induced bias

Clinical trials stand as pivotal elements in medical research, crucial for the evaluation and validation of new therapeutic interventions, drugs, and standards of care. These studies systematically assess the impacts of specific interventions on human subjects by juxtaposing them with control groups, either untreated or given a placebo (i.e., a treatment without therapeutic effects investigated in the treatment, e.g. harmless pill) [114]. The ethical and logistical challenges inherent in clinical trial recruitment necessitate not only enlisting a sufficient number of participants to ensure statistical power [58] but also striving for a sample that mirrors the diversity of the target population [114]. This stage poses an ethical question to the study’s conductor since the goal is to recruit an adequate number of participants to generate enough data to answer the research questions at hand, but it is usually impossible to choose a completely random sample group and at the same time representative of the general population or even the of the study’s population [48]. This endeavor is



417 crucial for minimizing *selection bias*, a form of bias that occurs when the trial population does not adequately represent  
418 the broader community, potentially skewing the trial's outcomes and applicability [63]. The selection bias is closely  
419 related and sometimes equated to the concepts of *underrepresentation bias* or *informative presence bias*. The informative  
420 presence bias occurs in instances when those who have poorer health have more data recorded than healthier patients  
421 or in other similar instances when one patient group is represented more in the sample than other groups but this  
422 composition does not reflect the proportions in the general population of the studied disease[63]. As a result, employed  
423 AI solutions would prioritize patients in better-represented groups and make significant errors in the interpretation and  
424 prediction of the health needs of the underrepresented population, thereby further inducing health disparities between  
425 these groups. In the identified literature, the underrepresentation bias was shown to affect the decision thresholds,  
426 administration of care, or the medical procedure conducted in the study with no other plausible source of bias affecting  
427 the decision.  
428  
429  
430

431 The under- and over-representation biases based on conclusions from previously conducted clinical trials come  
432 both from the self-selection in scientific publishing as well as the disparities in the socio-economic systems that define  
433 access to healthcare around the world. Publication bias, for instance, emerges from the tendency to publish studies with  
434 positive outcomes more frequently than those with negative or inconclusive results, leading to a skewed perception  
435 of an intervention's efficacy [96]. Another critical concern is the underrepresentation of certain demographic groups,  
436 either due to their scarcity in the general population or the presence of systemic barriers that deter participation and  
437 thereby create missingness in the dataset. Such disparities can introduce "class imbalances," particularly detrimental in  
438 studies of rare diseases or for small communities with a certain sensitive feature on which AI bases prediction. This  
439 characteristic can significantly bias the development and evaluation of data-driven health solutions [128]. For example,  
440 AI models trained on datasets predominantly comprising data from one racial group are found not to perform accurately  
441 when applied to underrepresented groups [14]. The unrepresentativeness may occur due to the small samples (e.g. in  
442 minority populations), which may lead to underestimation or overestimation of risks in the subpopulation relative to  
443 the majority producing inaccurate or misleading recommendations. Deep learning algorithms used to predict acute  
444 kidney injury in adults significantly underperformed for female patients which represented just 6.4% of the data in the  
445 training dataset [126]. Similarly, the breast cancer survival rate algorithm underperformed for Black women which  
446 represented only 7.8% of the data [30]. Moreover, systematic reviews have highlighted significant gaps in the inclusion  
447 of racial and ethnic information in clinical research, underscoring the challenge of achieving representativeness [2]. Out  
448 of 38 studies that met the criteria of inclusion in the meta-analysis, 28 did include racial or ethnographic information  
449 (73%), but only 17 studies (45%) included information on Hispanic participation while comprising a mere 11.6% of  
450 participants out of the general population tested [109]. A database study of all reported trials supporting FDA oncology  
451 drug approvals granted between July 2008 and June 2018 showed that only 63% of trials reported at least one race  
452 and 36.9% had no mention of race. In 7.8% of trials that reported on all four races (White, Asian, Black, or Hispanic),  
453 only White patients' representation matched their proportion based on cancer incidence and mortality in the United  
454 States, while Black and Hispanic populations were consistently underrepresented, and Asian overrepresented [87]. The  
455 disproportionality between clinical trial enrollment of certain ethnic minority groups and the prevalence of diseases  
456 among them is demonstrated empirically [12]. Less than 5% of African Americans participated in Diabetes mellitus  
457 clinical trials and only 32% took part in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack  
458 Trial [12]. Participation in medication and therapy programs in the U.S. also indicated racial disparities, as patients  
459 with Alzheimer's disease and related dementias (ADRD) and diabetes were tested for their enrollment in the Medicare  
460 Medication Therapy Management (MTM) program. Significant disparities between Whites and Blacks were found  
461  
462  
463  
464  
465  
466  
467  
468

469 within all study cohorts, as Blacks had significantly lower odds of enrolling in MTM programs compared to Whites  
470 [20]. Gender disparities are evident in the underrepresentation of women in cardiovascular trials. Only 33% to 38% of  
471 all clinical trials conducted between 2010-2020 consisted of women [12]. The lower participation rates of women in  
472 trials for hypertension, diabetes, hyperlipidemia, coronary artery disease, heart failure, and arrhythmia in recent years  
473 contradicted the prevalence of these diseases in women.  
474

475 The repercussions of underrepresentation extend beyond the accuracy of clinical predictions to affect treatment  
476 paradigms and health outcomes across different population segments. Disparities in trial participation rates can lead  
477 to the development of treatment standards that do not adequately address the needs of all groups, particularly those  
478 historically marginalized or with limited access to healthcare resources [87]. Even more, the informative presence  
479 bias does not occur only between subjects, but also within-subject data when analyzing longitudinal patterns in the  
480 development of the disease. For example, longitudinal analyses of biomarkers are likely to show bias in hazard ratio  
481 estimates if biomarker values are analyzed predominantly based on informative visits (initiated by a patient), rather  
482 than noninformative visits (like routine check-ups). [56]. Even when both informative and noninformative visits are  
483 combined, the informative bias in biomarkers longitudinal analysis will form if the biomarkers are more volatile over  
484 time [63]. Addressing these challenges requires concerted efforts to enhance the inclusivity and equity of clinical  
485 research, ensuring that the benefits of medical advancements are accessible to all segments of society.  
486  
487  
488  
489

## 490 **5.2 Missing, incomplete information and poor logging of information**

491 Missing or incomplete information and poor logging of information refer to bias arising from the quality of electronic  
492 health records used for research. EHRs are susceptible to biases stemming from missing, incomplete, or inaccurately  
493 logged information. These inaccuracies can arise from various factors such as medical staff oversight, technical issues  
494 in logging data, poor labeling, patient non-disclosure, or systemic constraints. This review identifies studies addressing  
495 the prevalence and implications of such data deficiencies.  
496  
497

498 Besides the fact that some of the subgroups in a population may intrinsically have smaller samples in the population,  
499 other important reasons for underrepresentation in databases may have intrinsically social causes which may lead  
500 to the lower representation of some groups in the databases due to the missing information. Examples include the  
501 underrepresentation of groups based on some structural barriers like the socioeconomic lack of access (for example,  
502 to medical care) or subpopulation's self-imposed exclusion due to the distrust in the system that may drive under-  
503 representation or other issues in self-reporting. Disparities in cancer diagnosis are found to be explainable by health  
504 insurance coverage, such that racial/ethnic minority children and adolescents are more likely to have an advanced  
505 cancer diagnosis compared with non-Hispanic Whites, which may relate to the lack of consistent healthcare access  
506 [136]. Neighborhood socioeconomic status (SES), rather than family SES, explained around 29% of racial disparities  
507 in the average rate of change in blood pressure trajectories for Black American versus non-Hispanic White preterm  
508 children [49]. Healthcare access due to social reasons, device allocation that differs between rural and urban areas or  
509 between hospitals, and measurement frequency which can be affected by the patient/doctor ratios or the location of the  
510 hospital, can all influence which patients will be included in the databases and with which likelihood [26].  
511  
512

513 In the realm of EHRs, a significant bias source is the inconsistent or erroneous recording of information, which  
514 can be seen as the labeling bias. For instance, discrepancies are found in the coding of uveitide ICD10 across the two  
515 most prominent EHR systems (Epic and MDIntelleSys) yielding different codes in 13 out of 27 diseases, leading to  
516 potential data fragmentation and analysis impact [108]. Moreover, multiple codes were used to describe more than  
517 one specific disease. Therefore, combining data from different EHR systems can lead to fragmented and incomplete  
518  
519  
520

521 data and may affect downstream analysis and conclusion. Moreover, socioeconomic data is often unrecorded, and  
522 analyses based solely on complete cases introduce considerable selection bias [81]. This bias was evident in research  
523 on epithelial ovarian cancer, which indicated that missing data is not at random since the cases with missing data  
524 correlated with poorer survival outcomes [126]. Biases arising from missing or poor quality data are also likely to  
525 have led to disparities in healthcare services to LGBTQ patients [60]. Missingness and labeling biases can become  
526 amplified over time or in subsequent iterations of the data. Biases in EHR can skew large-scale studies, as illustrated  
527 by a study examining the time-varying biases in genome-wide association studies, which could lead to inaccurate  
528 gene-phenotype associations [119]. The off-label use of open databases is another concern, potentially generating  
529 biased machine learning models due to overlooked bias in data collection or processing, a phenomenon dubbed "data  
530 crime" [119]. Therefore, researchers who look to incorporate two or more datasets in model development to increase  
531 robustness and generalizability ultimately may introduce this form of bias into their model.

532 Data preparation adds another layer of complexity, introducing biases through labeling, coding, and the use of proxies  
533 for social categories. For example, differences in data labeling practices between Europe and the USA can significantly  
534 affect AI applications in pathology [102]. In the US, it is little known that some European staining solutions include  
535 saffron dye for improved fibrous tissue delineation, which may not even be indicated in the data description, since such  
536 information may be assumed as given [102]. Often different labeling terminology and standards are employed across  
537 countries, inducing variation and confusion in the use of terms and abbreviations. This issue extends to variations  
538 in clinical note-taking and terminology, which influence machine learning predictions in critical care mortality and  
539 psychiatric readmissions [29]. Labeling biases and poor logging of information are likely to occur in numerous instances  
540 as medical professionals typically log information post-hoc and perceive these tasks as an administrative burden.

541 Even when data is labeled correctly, it is often not advisable to use some features or models that must use proxies of  
542 variables for the information that is missing. The use of proxies to circumvent the direct use of sensitive attributes like  
543 race, gender, and ethnicity in health predictions introduces measurement biases. A seminal study demonstrated that  
544 using healthcare costs as a proxy for healthcare needs led to a biased prioritization of affluent White patients over Black  
545 American patients with comparable disease burdens [105]. This example underscores the need for careful consideration  
546 in data handling and model development to prevent perpetuating existing disparities.

### 554 5.3 Implicit Human Biases

555 In addition to data-related biases, healthcare practices and Electronic Health Records (EHRs) are influenced by the  
556 inherent, often unconscious biases of health professionals. These implicit biases entail the subconscious stereotypes  
557 healthcare providers hold, leading to skewed assessments of patient needs and medical conditions based on sensitive  
558 attributes such as race, gender, socioeconomic status, and medical history. These biases, which are typically involuntary  
559 and irrational, tend to be related to the implicit beliefs of healthcare professionals about the natural differences between  
560 genders, races, or ethnical minorities [45].

561 Healthcare professionals, like the general population, harbor implicit biases that reflect societal stereotypes about  
562 race, gender, and ethnicity. Such biases, inadvertently recorded in EHRs, contribute to perpetuating healthcare inequities.  
563 The training of medical students, which emphasizes pattern recognition and stereotypical symptoms, may further embed  
564 these biases. Consequently, implicit bias adversely impacts diagnostic and treatment decisions, thereby exacerbating  
565 healthcare disparities. For instance, disparities in diagnosing malingering—where patients are unjustly accused of  
566 exaggerating medical issues—disproportionately affect men and Black patients [132]. Encoding such diagnosing in EHR  
567 has serious consequences on future medical care, the likelihood of admittance and receiving treatment.

573 Implicit biases have tangible consequences on medical care, particularly for marginalized groups such as ethnic  
574 minorities, immigrants, economically disadvantaged individuals, sexual minorities, and others, leading to systemic  
575 under-treatment and diagnostic inaccuracies. These biases manifest in various healthcare aspects, including initial  
576 disease diagnosis, and the timeliness and accuracy of diagnoses and treatments across several medical domains  
577 like neurodegenerative, pulmonary, cardiac diseases, and oncology [16, 84]. Implicit bias has been shown to lead to  
578 substantive physician errors in predicting heart attack such that physicians overtest predictably low-risk patients and  
579 under test predictably high-risk patients because they predominantly rely on simple heuristics like chest pain [101]. An  
580 AI model that learns from the resulting data will inevitably be biased in the same way.  
581  
582

583 Research also indicates that implicit biases contribute to significant physician errors, such as the misallocation of  
584 diagnostic resources based on simplistic heuristics rather than patient risk levels [122]. Patient reluctance to disclose  
585 information about prescribed medications to clinicians may signal mistrust stemming from previous experiences or the  
586 healthcare provider's perceived judgment about the patient's treatment adherence [29, 86].  
587  
588

#### 589 **5.4 Referral and admission bias (including access to care)**

590 Biases related to clinician referrals and patient admissions significantly influence healthcare access and research partici-  
591 pation. An admission bias arises when the selection criteria for research participation or medical care disproportionately  
592 exclude individuals based on discriminatory characteristics, leading to skewed study populations or unequal access to  
593 care [43]. Similarly, referral bias occurs due to systematic differences in who gets referred for further evaluation or  
594 treatment, often disadvantaging certain groups [33]. An example may be seen in studies that showed that minorities  
595 with worse objective dry eye parameters received fewer prescription treatments or procedures than White patients [33].  
596  
597

598 This review focused on identifying studies that highlighted disparities in access to care and referral patterns across  
599 different treatments, such as cancer prognosis, cardiovascular diseases, and appendicitis, based on sociodemographic  
600 factors rather than objective medical criteria. These barriers often stem from implicit biases and socioeconomic  
601 constraints, leading to delayed or foregone care [64, 124]. The impact of racial and socioeconomic status on access to  
602 care is well-documented, with minority groups and those from lower socioeconomic backgrounds facing significant  
603 barriers to receiving treatment and diagnoses at earlier, more treatable disease stages [14, 18]. Lower socioeconomic  
604 strata patients were diagnosed at a later stage of anal cancer disease, had worse survival than wealthier patients, and  
605 were less likely to receive radiation therapy [23].  
606  
607

608 Furthermore, studies have shown that disparities in care access and referral patterns manifest early in life, with  
609 children from African American backgrounds experiencing lower admission rates and follow-up care in intensive  
610 settings [59]. Gender disparities also contribute to these biases, affecting referral rates to specialists and hospital  
611 admissions [5]. For instance, young women are less likely to undergo certain procedures like percutaneous coronary  
612 intervention compared to their male counterparts, resulting in higher in-hospital adverse event rates [109].  
613  
614

615 Socioeconomic status further compounds these issues, with individuals from lower socioeconomic strata receiving  
616 suboptimal care for conditions such as blood pressure management [44]. These systematic biases not only impact  
617 patient outcomes but also influence the representation of diverse populations in clinical data, perpetuating biases in  
618 data-driven healthcare solutions.  
619  
620

621 In summary, implicit biases related to clinician referrals and patient admissions create significant barriers to equitable  
622 healthcare access and treatment. Addressing these biases requires concerted efforts to ensure that healthcare and  
623 research practices are inclusive and representative of the diverse populations they serve.  
624

## 5.5 Diagnosis, prognosis, or risk disparities bias

In addition to the biases in admission and referral to further treatment, implicit biases also occur at the later stages of the patient's journey. Disparities in the diagnosis, prognosis, and risk assessment within medical datasets emerge as a critical form of inherent bias, significantly influenced by patient demographics such as gender, SES, and race. A notable body of research highlights these disparities, particularly in the context of cancer diagnosis and treatment initiation stages. For instance, disparities based on SES and racial groups are evident in the diagnosis and treatment of various cancers [23, 132, 136]. Specifically, racial and ethnic disparities have been documented in the delayed diagnosis of appendicitis among Black children, where delays were associated with prior emergency department visits and the absence of imaging during these visits [59].

Moreover, disparities in cancer diagnosis have been linked to differences in health insurance coverage, leading to advanced cancer diagnoses among racial/ethnic minority children and adolescents compared to their non-Hispanic White counterparts, attributed to inconsistent healthcare access [136]. Similarly, patients from lower socioeconomic backgrounds are diagnosed at later stages of diseases such as anal cancer, experiencing poorer outcomes and reduced access to treatments like radiation therapy [23]. The influence of neighborhood SES, as opposed to individual or family SES, accounts for a significant portion of the racial disparities observed in health outcomes, such as blood pressure trajectories among preterm children [49].

Access to healthcare and the allocation of medical devices, which varies between rural and urban locations or among different hospitals, along with disparities in the frequency of medical assessments, can dictate the inclusion of patients in medical databases, further perpetuating these biases [44].

Additionally, conditions such as insulin resistance have been shown to contribute to racial disparities in breast cancer prognosis, highlighting the complex interplay between medical conditions and demographic factors [50]. Heightened HIV risk is found among Black men compared to White men, underscoring the role of specific risk factors unique to different racial groups [57].

This review identified thirty studies showcasing this category of bias, marking it as the most prevalent type of bias encountered. Such findings underscore the urgent need for strategies to mitigate these disparities, ensuring equitable healthcare outcomes across all patient demographics.

## 5.6 Data bias in medical devices and algorithms

Medical machinery bias stems from discrepancies in how algorithms are programmed and the calibration of devices, potentially leading to measurement inaccuracies for patients with diverse ethnic, physiological, and biological characteristics. This bias may arise from technical errors in medical equipment [106, 116, 127, 133] or from underlying differences in measurements due to factors not related to the patient's medical condition. Within medical facilities, patients undergo frequent automatic testing using equipment such as pulse oximeters, EKGs, ECGs, and thermometers, alongside semi-automatic tests involving healthcare professionals (e.g., hematology analyzers, biochemistry analyzers, scales, and blood glucose monitors). The outcomes of these assessments play a crucial role in patient evaluation and treatment planning.

We noted nine articles in this review highlighting this form of bias. Specifically, pulse oximeters exhibit reduced accuracy in patients with darker skin pigmentation, an issue attributed to device miscalibration and the lack of diversity in development phases [106, 116, 127, 133]. Similar disparities in device accuracy affecting measurements like oxygen saturation, body temperature, and blood pressure [44] have been documented, often resulting from insufficiently diverse

677 calibration populations [26]. A systematic review of mechanical ventilation studies found that AI applied to mechanical  
678 ventilation has limited external validation and model calibration, with a substantial risk of bias, significant gaps in  
679 reporting, and poor code and data availability [53]  
680

681 Such discrepancies in device performance can introduce biases into clinical data, potentially influencing treatment  
682 decisions, such as the administration of supplemental oxygen or the preference for certain temperature measurement  
683 methods, thereby affecting diagnoses and treatments for specific racial subgroups. For example, studies have identified  
684 an increased risk of occult hypoxemia in Black patients compared to White patients with identical oxygen saturation  
685 measurements [116, 133].  
686

687 Additionally, benign ethnic neutropenia (BEN), a condition where individuals (commonly of African, Middle Eastern,  
688 and West Indian descent) present with neutropenia (absolute neutrophil count < 1500/ $\mu$ L) without an increased  
689 infection risk, exemplifies bias stemming from physiological variances across different patient groups [4, 9]. The biased  
690 interpretation of such measurements or conditions perpetuates sub-optimal care for specific patient demographics,  
691 further encoded into EHR systems, highlighting the critical need to address medical machinery bias to ensure equitable  
692 healthcare delivery. In addition, substantial biases in AI algorithms arise due to implicit human biases of programmers  
693 who develop algorithms, similar to the implicit biases outlined for health professionals. It is well documented that  
694 experts in computer science and AI developers are a fairly homogeneous group with the mental mindset of a Western  
695 White male [17].  
696  
697  
698

## 699 **6 DISCUSSION**

### 700 **6.1 How diverse sources of biases can perpetuate one another**

701  
702 In the preceding discussions, we have endeavored to delineate and exemplify various biases originating from distinct  
703 sources. Adopting a process-oriented perspective, we aim to elucidate how these diverse sources of biases can interact  
704 and potentiate each other. Figure 2 conceptualizes a typical patient journey, highlighting how inherent biases might  
705 emerge at various junctures and proliferate over time within a technocratic framework that leverages data-driven  
706 AI systems in healthcare. This depiction underscores the cumulative nature of biases, illustrating their potential to  
707 compound and exacerbate disparities in patient care and outcomes within AI-enhanced healthcare environments.  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728

729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780




Fig. 2. Illustration of the source of bias on a timeline. A patient's timeline from inception.  $t_0$  represents a clinical trial that results in a biased diagnosis threshold towards specific patient populations, and  $t_1 - t_4$  represents the lifetime of a patient in the healthcare system until a particular time when the patient receives biased care due to implicit bias, or bias in medical machinery. Incomplete information and biased clinical decisions are logged into the EHR system. At time  $t_5$ , a retrospective ML model is developed based on previously collected data. Which consequently results in biased inference, perpetuating the bias toward other patients

Consider a hypothetical patient, Anne, at the initial point in time,  $t_0$ , who begins experiencing symptoms necessitating a medical evaluation and possibly treatment. The primary step involves comparing her symptoms and medical history against existing knowledge and clinical trial data. Depending on Anne's ethnicity, gender, or socioeconomic status, she might find that the algorithms governing admission prioritize her case differently compared to other patients with similar symptoms. In the second stage, while waiting for admission, Anne might struggle with self-administered questionnaires, especially questions about her socioeconomic status and sexual orientation, due to their complexity or her reluctance to provide comprehensive responses. Objecting to these questions on moral grounds and privacy concerns, she decides to omit some answers and fabricate some others. Subsequently, Anne meets with a healthcare professional who, despite their best intentions, appears significantly different from her in many respects, making it difficult for her to feel understood. This professional relies on an AI healthcare system that seems unable to fully "understand" Anne. The system, concurring with the doctor, diagnoses her in a manner that suggests she does not require hospital admission or further treatment. Left uncertain about her actual health risk despite her symptoms, Anne wonders if the system simply fails to recognize her unique needs. She is discharged, and the AI model, employing machine learning algorithms, records her case to refine future treatment predictions for similar cases. At the end of the shift, the doctor writes a very short note about Anne's case in the records. Despite Anne's experience, the hospital lauds the model for its operational efficiency.

## 6.2 Discussion of evidence

While this review aims to categorize and point out possible sources of hidden biases in EHRs, we emphasize this review serves only as a "call to action" and is far from covering the entire spectrum of biases currently residing in EHRs and medical data in general. This scoping review synthesizes the documented sources of bias in the current literature on EHRs, incorporating 116 articles that met the inclusion criteria. The review introduces inherent or hidden bias within EHR data, which poses significant challenges to developing machine learning models and the generalizability and precision of research findings. The inherent bias in EHRs can significantly affect retrospective studies and algorithmic model development. This review proposes a categorization of inherent bias into six distinct categories based on the source of bias: implicit clinician bias, bias in medical machinery, disparities in diagnosis, prognosis or risk, referral

781 and admission bias, biases resulting from clinical trials, and issues related to missing, incomplete, or poorly logged  
782 information. Increased discussion about potential sources of biases in healthcare has increased awareness, but diverse  
783 sources of bias identified in this review are still scarcely accounted for in research and development of AI solutions in  
784 healthcare.  
785

786 The presence of these biases was consistent across various settings, populations, and EHR systems, indicating a  
787 broad applicability of this categorization framework. Notably, the review highlights the frequent misidentification or  
788 underreporting of bias types in the literature, where terms like disparities, equity, or differences in risk or prevalence in  
789 disease diagnosis often mask inherent bias.  
790

791 The methodology of this review, grounded in clinical and human-machine interaction insights followed by a targeted  
792 literature search, has led to a focused and informative collection of articles. Referral and admission bias emerged as  
793 the most frequently documented category, suggesting that disparities in healthcare access—driven by factors like race,  
794 gender, and SES precede and influence the care process, thus introducing a selection bias in the development of machine  
795 learning models. The prominence of referral and admission bias reporting is understandable given that the objective  
796 data for analyzing this bias is more readily available. However, this finding also warns about the importance of providing  
797 empirical evidence on other sources of bias and the importance that transparency of databases and access to open  
798 sources have in the mitigation of AI biases.  
799  
800

801 The second most prevalent source of bias identified involves disparities in diagnosis, prognosis, or risk, highlighting  
802 how different risk factors and demographics can affect patient outcomes across various diseases, notably in oncology  
803 [23, 132]  
804

805 Despite these challenges, advancements in artificial intelligence offer potential mitigations for human-induced biases.  
806 For instance, AI models have shown promise in addressing biases in radiographic measures and in recognizing the  
807 physical causes of pain across racial and socioeconomic groups, thereby accounting for a larger proportion of disparities  
808 in pain than traditional measures. For example, relative to standard measures of pain severity graded by radiologists,  
809 which accounted for only 9% of racial disparities in pain, AI predictions accounted for 43% of disparities, with similar  
810 results for lower-income and less-educated patients which stem from the racial and socioeconomic diversity of the  
811 training set [27].  
812

813 This review underscores the critical need for awareness and corrective measures against inherent biases in EHR data  
814 to improve the fairness and effectiveness of machine learning applications in healthcare.  
815

816 Addressing racial and other disparities due to data incompleteness is crucial for enhancing equity in health systems.  
817 Protocols and guidelines for routinely collecting and reporting disaggregated ethnicity data are recommended [16].  
818 Initiatives like The HL7 Gravity project, which seeks to standardize social determinants of health measures for  
819 interoperable electronic health information exchange, are pivotal [98]. Synthetic data approaches in machine learning  
820 also play a vital role in compensating for the lack of diverse annotated medical data, ensuring analytical processes  
821 reflect the general population's diversity [28, 111].  
822

823 Implicit clinician or healthcare provider bias represents a significant challenge, impacting ground truth (GT) for  
824 retrospective models and hindering the ability of models to eliminate existing biases. Addressing this requires educational  
825 interventions to increase awareness among medical students and practitioners [5]. Efforts to increase diversity within  
826 hospitals and medical schools may contribute to reducing such biases.  
827

828 The literature indicates that machine or AI bias, resulting from historical biases in diagnoses, prognoses, and clinical  
829 decisions logged in EHRs, can be perpetuated by machine learning (ML) models. This underscores the necessity for  
830 critical evaluation of data and the acknowledgment of potential biases in medical machinery, such as the differential  
831



833 risks indicated by pulse oximeters for patients of different races with identical readings [127], and varied infection risks  
834 for patients with benign ethnic neutropenia (BEN) [9].

835 Furthermore, missing or poorly logged information in EHRs poses an additional source of inherent bias in EHR. This  
836 includes compatibility issues with ICD diagnosis codes across different EHR systems, which can introduce biases into  
837 ML models developed using data from multiple sources [108]. Researchers aiming to enhance model robustness and  
838 generalizability by integrating multiple datasets must navigate these challenges to avoid introducing biases.  
839  
840

### 841 **6.3 Limitations**

842 This scoping review is subject to several limitations that warrant careful consideration. Primarily, the inclusion of articles  
843 exclusively from PubMed and Web of Science introduces a potential database selection bias, potentially overlooking  
844 relevant research published in other languages or databases. Additionally, by focusing on peer-reviewed articles from  
845 2016 to 2023, the review may omit earlier or more recent developments related to bias in electronic health records  
846 (EHRs). The exclusion of non-peer-reviewed literature could also contribute to publication bias, possibly exaggerating  
847 the prevalence of inherent bias, since the studies that show the bias may be more likely to get published than studies  
848 with inconclusive or nonsignificant results. Furthermore, the absence of a quality and rigor assessment for the included  
849 studies might impact the review's reliability. Lastly, the generalizability of the findings is potentially limited, as the  
850 review may not encompass bias sources specific to certain demographics, healthcare environments, or EHR systems.  
851 Future research should aim to mitigate these limitations and provide a more comprehensive understanding of bias in  
852 EHRs.  
853  
854  
855  
856  
857

### 858 **6.4 Conclusions**

859 We want to emphasize that we approach the conclusions with epistemic humility acknowledging that the current  
860 evidence only scratches the surface of the potential problems of AI implementation in healthcare globally and due  
861 to the centralization of evidence in Western societies we lack a holistic picture from those who have not gotten so  
862 far "a seat at the proverbial table". This article aims to highlight these inequalities and call for more research into the  
863 sources of bias that permeate global health records and AI model developments. With that said, the integration of AI  
864 in healthcare presents a transformative potential for enhancing efficiency, enabling the analysis of vast datasets, and  
865 facilitating the extraction of actionable insights to inform decision-making at reduced costs. AI's capabilities extend to  
866 more accurate screening and detection of dementia risks [14] and improve predictions of long-term recurrence risks  
867 for ischemic cerebrovascular events post-discharge [143]. Moreover, AI advancements contribute to the refinement  
868 of risk scoring and mortality prediction models for a variety of conditions [71]. However, the effectiveness of these  
869 advancements is contingent upon the availability of accurate and unbiased data, as biases present in Electronic Health  
870 Records (EHRs) can significantly impact diagnosis and treatment decisions. Contrary to the focus on machine bias  
871 in computer science literature, our review identifies six critical sources of "inherent biases" within EHRs that are  
872 less recognized and addressed in the medical field. These biases include (a) implicit clinician bias, (b) bias in medical  
873 machinery, (c) disparities in diagnosis or risk assessment, (d) referral and admission bias, (e) biases stemming from  
874 clinical trials, and (f) the presence of missing or incomplete information.  
875  
876  
877  
878

879 These challenges contribute to perpetuating disparities and biases in algorithmic solutions, affecting their fairness,  
880 outcomes, and the trust of professionals and the public place in AI technologies. Our findings add to the importance of  
881 addressing these inherent biases enhancing the effectiveness and adoption of data-driven solutions and AI in healthcare.  
882  
883  
884

## 7 ACKNOWLEDGMENTS

We express our sincere appreciation to the Big Biomedical Data Lab at BGU for their valuable input and discussions. Special thanks are also extended to Natalie Anne Jansen, M.D., and Alon Dagan, M.D., from the Beth Israel Deaconess Medical Center, for their insightful contributions to our discussions.

## 8 FUNDING

LAC is funded by the National Institute of Health through NIBIB R01 EB017205.

## 9 CONFLICTS OF INTEREST

The authors report no conflict of interest in this review

## REFERENCES

- [1] AA Adejare, Y Gautam, J Madzia, and TB Mersha. Unraveling racial disparities in asthma emergency department visits using electronic healthcare records and machine learning. *JOURNAL OF ASTHMA*, 59(1):79–93, 1 2022.
- [2] Ritu Agarwal, Michelle Dugas, Jui Ramaprasad, Junjie Luo, Gujie Li, and Guodong Gao. Socioeconomic privilege and political ideology are associated with racial disparity in covid-19 vaccination. *Proceedings of the National Academy of Sciences*, 118(33):e2107873118, 2021.
- [3] J Agor, OY Ozaltin, JS Ivy, M Capan, R Arnold, and S Romero. The value of missing information in severity of illness score development. *JOURNAL OF BIOMEDICAL INFORMATICS*, 97, 9 2019.
- [4] Mohammed Shahriar Arefin, Alexander P Dumont, and Chetan A Patil. Monte carlo based simulations of racial bias in pulse oximetry. In *Design and Quality for Biomedical Technologies XV*, volume 11951, pages 8–12. SPIE, 2022.
- [5] S Arya, C Franco-Mesa, and Y Erben. An analysis of gender disparities amongst united states medical students, general surgery residents, vascular surgery trainees, and the vascular surgery workforce. *JOURNAL OF VASCULAR SURGERY*, 75(1):5–9, 1 2022.
- [6] Shipra Arya, Taylor A. Melanson, Elizabeth L. George, Kara A. Rothenberg, Manjula Kurella Tamura, Rachel E. Patzer, and Jason M. Hockenberry. Racial and sex disparities in catheter use and dialysis access in the united states medicare population. *Journal of the American Society of Nephrology : JASN*, 31(3):625–636, 3 2020. PMID: 31941721 PMCID: PMC7062210.
- [7] Deborah Assayag, Julie Morisset, Kerri A. Johansson, Athol U. Wells, and Simon L. F. Walsh. Patient gender bias on the diagnosis of idiopathic pulmonary fibrosis. *Thorax*, 75(5):407–412, 5 2020. publisher-place: England PMID: 32054644.
- [8] Suheil Albert Atallah-Yunes, Audrey Ready, and Peter E. Newburger. Benign ethnic neutropenia. *Blood Reviews*, 37:100586, 9 2019. PMID: 31255364 PMCID: PMC6702066.
- [9] ZA Awan, SM Al Amoudi, M Saboor, and HY Alkhalidy. Isolated neutropenia/benign ethnic neutropenia: A common clinical and laboratory finding in southern and western saudi arabia. *INTERNATIONAL JOURNAL OF GENERAL MEDICINE*, 14:451–457, 2021.
- [10] OA Babatunde, JM Eberth, TM Felder, R Moran, C Hughes-Halbert, S Truman, JR Hebert, S Heiney, and SA Adams. Racial disparities and diagnosis-to-treatment time among patients diagnosed with breast cancer in south carolina. *JOURNAL OF RACIAL AND ETHNIC HEALTH DISPARITIES*, 9(1):124–134, 2 2022.
- [11] Jack Badawy, Oanh Kieu Nguyen, Christopher Clark, Ethan A. Halm, and Anil N. Makam. Is everyone really breathing 20 times a minute? assessing epidemiology and variation in recorded respiratory rate in hospitalised adults. *BMJ quality safety*, 26(10):832–836, 10 2017. PMID: 28652259 PMCID: PMC5812442.
- [12] Sujana Balla, Sofia Elena Gomez, and Fatima Rodriguez. Disparities in cardiovascular care and outcomes for women from racial/ethnic minority backgrounds. *Current treatment options in cardiovascular medicine*, 22(12):75, 2020. PMID: 33223802 PMCID: PMC7669491.
- [13] Nicasia Beebe-Wang, Alex Okeson, Tim Althoff, and Su-In Lee. Efficient and explainable risk assessments for imminent dementia in an aging cohort study. *IEEE Journal of Biomedical and Health Informatics*, 25(7):2409–2420, 2021.
- [14] Nicasia Beebe-Wang, Alex Okeson, Tim Althoff, and Su-In Lee. Efficient and explainable risk assessments for imminent dementia in an aging cohort study. *IEEE Journal of Biomedical and Health Informatics*, 25(7):2409–2420, 7 2021. event-title: IEEE Journal of Biomedical and Health Informatics.
- [15] A Blanken, CJ Gibson, YM Li, AJ Huang, AL Byers, S Maguen, S Inslicht, and K Seal. Racial/ethnic disparities in the diagnosis and management of menopause symptoms among midlife women veterans. *MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY*, 29(7):877–882, 7 2022.
- [16] Andrew D. Boyd, Rosa Gonzalez-Guarda, Katharine Lawrence, Crystal L. Patil, Miriam O. Ezenwa, Emily C. O'Brien, Hyung Paek, Jordan M. Braciszewski, Oluwaseun Adeyemi, Allison M. Cuthel, Juanita E. Darby, Christina K. Zigler, P. Michael Ho, Keturah R. Fautrot, Karen Staman, Jonathan W. Leigh, Dana L. Dailey, Andrea Cheville, Guilherme Del Fiol, Mitchell R. Knisely, Keith Marsolo, Rachel L. Richesson, and Judith M. Schlaeger. Equity and bias in electronic health records data. *Contemporary Clinical Trials*, 130:107238, 7 2023.

- 937 [17] Meredith Broussard. *More than a glitch: Confronting race, gender, and ability bias in tech*. MIT Press, 2023.
- 938 [18] Rachel-Maria Brown, Samia Tamazi, Catherine R. Weinberg, Aeshita Dwivedi, and Jennifer H. Mieres. Racial disparities in cardiovascular risk and  
939 cardiovascular care in women. *Current cardiology reports*, 24(9):1197–1208, 9 2022. publisher-place: United States PMID: 35802234.
- 940 [19] JA Browning, CCS Tsang, XB Dong, JY Wan, MA Chisholm-Burns, CK Finch, JW Tsao, CL Liu, and JL Wang. Effects of medicare comprehensive  
941 medication review on racial/ethnic disparities in nonadherence to statin medications among patients with alzheimer’s disease: an observational  
942 analysis. *BMC HEALTH SERVICES RESEARCH*, 22(1), 2 2022.
- 943 [20] JA Browning, CCS Tsang, R Zeng, XB Dong, J Garuccio, JY Wan, MA Chisholm-Burns, CK Finch, JW Tsao, and JL Wang. Racial/ethnic disparities  
944 in the enrollment of medication therapy management programs among medicare beneficiaries with alzheimer’s disease and related dementias.  
945 *CURRENT MEDICAL RESEARCH AND OPINION*, 38(10):1715–1725, 10 2022.
- 946 [21] Federico Cabitza, Davide Ciucci, and Raffaele Rasoini. A giant with feet of clay: On the validity of the data that feed machine learning in medicine.  
947 In *Organizing for the Digital World: IT for Individuals, Communities and Societies*, pages 121–136. Springer, 2019.
- 948 [22] Kathi Canese and Sarah Weis. Pubmed: the bibliographic database. *The NCBI handbook*, 2(1), 2013.
- 949 [23] KB Celie, C Jackson, S Agrawal, C Dodhia, C Guzman, T Kaufman, N Hellenthal, D Monie, J Monzon, and L Ocegüera. Socioeconomic and gender  
950 disparities in anal cancer diagnosis and treatment. *SURGICAL ONCOLOGY-OXFORD*, 26(2):212–217, 6 2017.
- 951 [24] Damon Centola, Douglas Guilbeault, Urmimala Sarkar, Elaine Khoong, and Jingwen Zhang. The reduction of race and gender bias in clinical  
952 treatment recommendations using clinician peer networks in an experimental setting. *Nature communications*, 12(1):6585, 11 2021. PMID: 34782636  
953 PMID: PMC8593068.
- 954 [25] LC Chambers, CM Khosropour, DA Katz, JC Dombrowski, LE Manhart, and MR Golden. Racial/ethnic disparities in the lifetime risk of chlamydia  
955 trachomatis diagnosis and adverse reproductive health outcomes among women in king county, washington. *CLINICAL INFECTIOUS DISEASES*,  
956 67(4):593–599, 8 2018.
- 957 [26] Marie-Laure Charpignon, Joseph Byers, Stephanie Cabral, Leo Anthony Celi, Chrystinne Fernandes, Jack Gallifant, Mary E. Lough, Donald  
958 Mlombwa, Lama Moukheiber, Bradley Ashley Ong, Anupol Panitchote, Wasswa William, An-Kwok Ian Wong, and Lama Nazer. Critical bias in  
959 critical care devices. *Critical Care Clinics*, 0(0), 3 2023. publisher: Elsevier.
- 960 [27] Irene Y Chen, Emma Pierson, Sherri Rose, Shalmali Joshi, Kadija Ferryman, and Marzyeh Ghassemi. Ethical machine learning in healthcare.  
961 *Annual review of biomedical data science*, 4:123–144, 2021.
- 962 [28] Richard J Chen, Ming Y Lu, Tiffany Y Chen, Drew FK Williamson, and Faisal Mahmood. Synthetic data in machine learning for medicine and  
963 healthcare. *Nature Biomedical Engineering*, 5(6):493–497, 2021.
- 964 [29] S Chung, QW Huang, J LaMori, D Doshi, and RJ Romanelli. Patient-reported experiences in discussing prescribed medications with a health care  
965 provider: Evidence for racial/ethnic disparities in a large health care delivery system. *POPULATION HEALTH MANAGEMENT*, 23(1):78–84, 2 2020.
- 966 [30] AE Connor, M Kaur, JY Sheng, and JH Hayes. Racial disparities in mortality outcomes among women diagnosed with breast cancer in maryland:  
967 Impact of cardiovascular disease and clinical characteristics. *CANCER*, 128(4):727–736, 2 2022.
- 968 [31] Lily A. Cook, Jonathan Sachs, and Nicole G. Weiskopf. The quality of social determinants data in the electronic health record: a systematic review.  
969 *Journal of the American Medical Informatics Association : JAMIA*, 29(1):187–196, 12 2021. PMID: 34664641 PMID: PMC8714289.
- 970 [32] RB Correia, LPD Kohler, MM Mattos, and LM Rocha. City-wide electronic health records reveal gender and age biases in administration of known  
971 drug-drug interactions. *NPJ DIGITAL MEDICINE*, 2, 7 2019.
- 972 [33] David Cui, Priya M Mathews, Gavin Li, Lee Guo, Shanna VanCourt, Ian J Saldanha, and Esen Karamursel Akpek. Racial and ethnic disparities in  
973 dry eye diagnosis and care. *Ophthalmic Epidemiology*, 30(5):484–491, 2023.
- 974 [34] M Daher, M Al Rifai, RY Kherallah, F Rodriguez, D Mahtta, ED Michos, SU Khan, LA Petersen, and SS Virani. Gender disparities in difficulty  
975 accessing healthcare and cost-related medication non-adherence: The cdc behavioral risk factor surveillance system (brfss) survey. *PREVENTIVE  
976 MEDICINE*, 153, 12 2021.
- 977 [35] Rachel A Dahl, J Priyanka Vakkalanka, Karisa K Harland, and Joshua Radke. Investigating healthcare provider bias toward patients who use drugs  
978 using a survey-based implicit association test: Pilot study. *Journal of addiction medicine*, 16(5):557–562, 2022.
- 979 [36] Stacie L. Daugherty, Irene V. Blair, Edward P. Havranek, Anna Furniss, L. Miriam Dickinson, Elhum Karimkhani, Deborah S. Main, and Frederick A.  
980 Masoudi. Implicit gender bias and the use of cardiovascular tests among cardiologists. *Journal of the American Heart Association*, 6(12), 11 2017.  
981 PMID: 29187391 PMID: PMC5779009.
- 982 [37] MM Donneyong, MA Fischer, MA Langston, JJ Joseph, PD Juarez, P Zhang, and DM Kline. Examining the drivers of racial/ethnic disparities  
983 in non-adherence to antihypertensive medications and mortality due to heart disease and stroke: A county-level analysis. *INTERNATIONAL  
984 JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH*, 18(23), 12 2021.
- 985 [38] Xianglin Du. Racial disparities in health insurance, triple-negative breast cancer diagnosis, tumor stage, treatment and survival in a large nationwide  
986 seer cohort in the united states. *Molecular and clinical oncology*, 16(4):1–12, 2022.
- 987 [39] HR Duenas, C Seah, JS Johnson, and LM Huckins. Implicit bias of encoded variables: frameworks for addressing structured bias in ehr-gwas data.  
988 *HUMAN MOLECULAR GENETICS*, 29(R1):R33–R42, 9 2020.
- [40] J. H. Ellenberg. Selection bias in observational and experimental studies. *Statistics in Medicine*, 13(5-7):557–567, 4 1994. PMID: 8023035.
- [41] Andre Esteve, Brett Kuprel, Roberto A Novoa, Justin Ko, Susan M Swetter, Helen M Blau, and Sebastian Thrun. Dermatologist-level classification  
of skin cancer with deep neural networks. *nature*, 542(7639):115–118, 2017.

- 989 [42] Albert J Farias, Gabriela Toledo, Carol Y Ochoa, and Ann S Hamilton. Racial/ethnic disparities in patient experiences with health care in association  
990 with earlier stage at colorectal cancer diagnosis: findings from the seer-cahps data. *Medical Care*, 59(4):295–303, 2021.
- 991 [43] A Farrukh and J Mayberry. Apparent disparities in hospital admission and biologic use in the management of inflammatory bowel disease between  
992 2014–2018 in some black and ethnic minority (bem) populations in england (vol 2, pg 144, 2020). *GASTROINTESTINAL DISORDERS*, 3(3):127–128, 9  
993 2021.
- 994 [44] Aaron Findley. Low health literacy and older adults: meanings, problems, and recommendations for social work. *Social work in health care*,  
54(1):65–81, 2015. publisher-place: United States PMID: 25588097.
- 995 [45] Chloë FitzGerald and Samia Hurst. Implicit bias in healthcare professionals: a systematic review. *BMC Medical Ethics*, 18(1):19, 12 2017.
- 996 [46] V Fontil, L Pacca, BK Bellows, E Khoong, CE McCulloch, M Pletcher, and K Bibbins-Domingo. Association of differences in treatment intensification,  
997 missed visits, and scheduled follow-up interval with racial or ethnic disparities in blood pressure control. *JAMA CARDIOLOGY*, 7(2):204–212, 2  
998 2022.
- 999 [47] Peter Franks and Kevin Fiscella. Effect of patient socioeconomic status on physician profiles for prevention, disease management, and diagnostic  
1000 testing costs. *Medical Care*, 40(8):717–724, 8 2002. PMID: 12187185.
- 1001 [48] Lawrence M. Friedman, Curt D. Furberg, David L. DeMets, David M. Reboussin, and Christopher B. Granger. *Fundamentals of Clinical Trials*.  
1002 Springer International Publishing, Cham, 2015. DOI: 10.1007/978-3-319-18539-2.
- 1003 [49] TE Fuller-Rowell, DS Curtis, PK Klebanov, J Brooks-Gunn, and GW Evans. Racial disparities in blood pressure trajectories of preterm children:  
1004 The role of family and neighborhood socioeconomic status. *AMERICAN JOURNAL OF EPIDEMIOLOGY*, 185(10):888–897, 5 2017.
- 1005 [50] Emily J. Gallagher, Kezhen Fei, Sheldon M. Feldman, Elisa Port, Neil B. Friedman, Susan K. Boolbol, Brigid Killelea, Melissa Pilewskie, Lydia Choi,  
1006 Tari King, Anupma Nayak, Rebeca Franco, Daliz Cruz, Irini M. Antoniou, Derek LeRoith, and Nina A. Bickell. Insulin resistance contributes to  
1007 racial disparities in breast cancer prognosis in us women. *Breast cancer research : BCR*, 22(1):40, 5 2020. PMID: 32393319 PMCID: PMC7216707.
- 1008 [51] Emily J Gallagher, Giampaolo Greco, Sylvia Lin, Radhi Yagnik, Sheldon M Feldman, Elisa Port, Neil B Friedman, Susan K Boolbol, Brigid Killelea,  
1009 Melissa Pilewskie, et al. Insulin resistance and racial disparities in breast cancer prognosis: a multi-center cohort study. *Endocrine-related cancer*,  
29(12):693–701, 2022.
- 1010 [52] A Gallegos, R Dudovitz, C Biely, PJ Chung, TR Coker, E Barnert, AD Guerrero, PG Szilagyi, and BB Nelson. Racial disparities in developmental  
1011 delay diagnosis and services received in early childhood. *ACADEMIC PEDIATRICS*, 21(7):1230–1238, 9 2021.
- 1012 [53] Jack Gallifant, Joe Zhang, Maria del Pilar Arias Lopez, Tingting Zhu, Luigi Camporota, Leo A Celi, and Federico Formenti. Artificial intelligence  
1013 for mechanical ventilation: systematic review of design, reporting standards, and bias. *British Journal of Anaesthesia*, 128(2):343–351, 2022.
- 1014 [54] Milena A. Gianfrancesco, Suzanne Tamang, Jinoos Yazdany, and Gabriela Schmajuk. Potential biases in machine learning algorithms using  
1015 electronic health record data. *JAMA internal medicine*, 178(11):1544–1547, 11 2018. PMID: 30128552 PMCID: PMC6347576.
- 1016 [55] Judy Wawira Gichoya, Liam G McCoy, Leo Anthony Celi, and Marzyeh Ghassemi. Equity in essence: a call for operationalising fairness in machine  
1017 learning for healthcare. *BMJ health & care informatics*, 28(1), 2021.
- 1018 [56] Benjamin A Goldstein, Matthew Phelan, Neha J Pagdipati, and Sarah B Peskoe. How and when informative visit processes can bias inference  
1019 when using electronic health records data for clinical research. *Journal of the American Medical Informatics Association*, 26(12):1609–1617, 2019.
- 1020 [57] ND Goldstein, I Burstyn, and SL Welles. Bayesian approaches to racial disparities in hiv risk estimation among men who have sex with men.  
1021 *EPIDEMIOLOGY*, 28(2):215–220, 3 2017.
- 1022 [58] Rebecca F Gottesman and Roy Hamilton. Recruiting diverse populations in clinical trials: how do we overcome selection bias?, 2021.
- 1023 [59] Monika K. Goyal, James M. Chamberlain, Michael Webb, Robert W. Grundmeier, Tiffani J. Johnson, Scott A. Lorch, Joseph J. Zorc, Evaline  
1024 Alessandrini, Lalit Bajaj, Lawrence Cook, and Elizabeth R. Alpern. Racial and ethnic disparities in the delayed diagnosis of appendicitis among  
1025 children. *Academic emergency medicine : official journal of the Society for Academic Emergency Medicine*, 28(9):949–956, 9 2021. publisher-place:  
1026 United States PMID: 32991770.
- 1027 [60] C Grasso, H Goldhammer, RJ Brown, and BW Furness. Using sexual orientation and gender identity data in electronic health records to assess for  
1028 disparities in preventive health screening services. *INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS*, 142, 10 2020.
- 1029 [61] V Gupta, I Haque, J Chakraborty, S Graff, S Banerjee, and SK Banerjee. Racial disparity in breast cancer: can it be mattered for prognosis and  
1030 therapy. *JOURNAL OF CELL COMMUNICATION AND SIGNALING*, 12(1):119–132, 3 2018.
- 1031 [62] D Hardy and DIY Du. Socioeconomic and racial disparities in cancer stage at diagnosis, tumor size, and clinical outcomes in a large cohort of  
1032 women with breast cancer, 2007–2016. *JOURNAL OF RACIAL AND ETHNIC HEALTH DISPARITIES*, 8(4):990–1001, 8 2021.
- 1033 [63] Joanna Harton, Nandita Mitra, and Rebecca A Hubbard. Informative presence bias in analyses of electronic health records-derived data: a  
1034 cautionary note. *Journal of the American Medical Informatics Association*, 29(7):1191–1199, 7 2022.
- 1035 [64] Shaakir Hasan, Stanislav Lazarev, Madhur Garg, Keyur Mehta, Robert H Press, Arpit Chhabra, J Isabelle Choi, Charles B Simone, and Daniel  
1036 Gorovets. Racial inequity and other social disparities in the diagnosis and management of bladder cancer. *Cancer Medicine*, 12(1):640–650, 2023.
- 1037 [65] Y Hashimoto, M Shiina, P Dasgupta, P Kulkarni, T Kato, RK Wong, Y Tanaka, V Shahryari, S Yamamura, S Saini, GR Deng, ZL Tabatabai, S Majid,  
1038 and R Dahiya. Upregulation of mir-130b contributes to risk of poor prognosis and racial disparity in african-american prostate cancer. *CANCER  
1039 PREVENTION RESEARCH*, 12(9):585–598, 9 2019.
- 1040 [66] "HealthIT.gov". Laws, regulation, and policy | healthit.gov. [Online; accessed 2023-12-17].
- [67] Samuel Henly, Gaurav Tuli, Sheryl A. Kluberg, Jared B. Hawkins, Quynh C. Nguyen, Aranka Anema, Adyasha Maharana, John S. Brownstein, and  
Elaine O. Nsoesie. Disparities in digital reporting of illness: A demographic and socioeconomic assessment. *Preventive medicine*, 101:18–22, 8 2017.

- 1041 PMID: 28528170 PMID: PMC5553633.
- 1042 [68] NR Henry, AC Hanson, PJ Schulte, NS Warner, MN Manento, TJ Weister, and MA Warner. Disparities in hypoxemia detection by pulse oximetry  
1043 across self-identified racial groups and associations with clinical outcomes". *CRITICAL CARE MEDICINE*, 50(2):204–211, 2 2022.
- 1044 [69] Alexander Hoerbst and Elske Ammenwerth. Electronic health records. *Methods of information in medicine*, 49(04):320–336, 2010.
- 1045 [70] JA Holmes and RC Chen. Racial disparities in time from diagnosis to treatment for stage i non-small cell lung cancer. *JNCI CANCER SPECTRUM*,  
1046 2(1), 1 2018.
- 1047 [71] Nianzong Hou, Mingzhe Li, Lu He, Bing Xie, Lin Wang, Rumin Zhang, Yong Yu, Xiaodong Sun, Zhengsheng Pan, and Kai Wang. Predicting 30-days  
1048 mortality for mimic-iii patients with sepsis-3: a machine learning approach using xgboost. *Journal of Translational Medicine*, 18(1):462, 12 2020.
- 1049 [72] D Islek, MK Ali, A Manatunga, A Alonso, and V Vaccarino. Racial disparities in hospitalization among patients who receive a diagnosis of acute  
1050 coronary syndrome in the emergency department. *JOURNAL OF THE AMERICAN HEART ASSOCIATION*, 11(19), 10 2022.
- 1051 [73] YZ Jin, S Schneeweiss, D Merola, and KJ Lin. Impact of longitudinal data-completeness of electronic health record data on risk score misclassification.  
1052 *JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION*, 29(7):1225–1232, 6 2022.
- 1053 [74] M. M. Joffe. Confounding by indication: the case of calcium channel blockers. *Pharmacoepidemiology and Drug Safety*, 9(1):37–41, 1 2000. PMID:  
1054 19025800.
- 1055 [75] Tiffani J. Johnson, Daniel G. Winger, Robert W. Hickey, Galen E. Switzer, Elizabeth Miller, Margaret B. Nguyen, Richard A. Saladino, and Leslie  
1056 R. M. Hausmann. Comparison of physician implicit racial bias toward adults versus children. *Academic pediatrics*, 17(2):120–126, 3 2017. PMID:  
1057 27620844 PMID: PMC5337439.
- 1058 [76] DD Jones. Examining the unconscious racial biases and attitudes of physicians, nurses, and the public: Implications for future health care education  
1059 and practice. *HEALTH EQUITY*, 6(1):375–381, 5 2022.
- 1060 [77] YJ Juhn, E Ryu, CI Wi, KS King, M Malik, S Romero-Brufau, CH Weng, S Sohn, RR Sharp, and JD Halamka. Assessing socioeconomic bias in machine  
1061 learning algorithms in health care: a case study of the houses index. *JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION*,  
1062 29(7):1142–1151, 6 2022.
- 1063 [78] EJ Kim, T Kim, J Conigliaro, JM Liebschutz, MK Paasche-Orlow, and AD Hanchate. Racial and ethnic disparities in diagnosis of chronic medical  
1064 conditions in the usa. *JOURNAL OF GENERAL INTERNAL MEDICINE*, 33(7):1116–1123, 7 2018.
- 1065 [79] BL Kinlock, RJ Thorpe, DL Howard, JV Bowie, LE Ross, DO Fakunle, and TA LaVeist. Racial disparity in time between first diagnosis and initial  
1066 treatment of prostate cancer. *CANCER CONTROL*, 23(1):47–51, 1 2016.
- 1067 [80] N Lamba, E Mehanna, RB Kearney, PJ Catalano, DA Haas-Kogan, BM Alexander, DN Cagney, KA Lee, and AA Aizer. Racial disparities in supportive  
1068 medication use among older patients with brain metastases: a population-based analysis. *NEURO-ONCOLOGY*, 22(9):1339–1347, 9 2020.
- 1069 [81] S Lamy, F Molinie, L Daubisse-Marliac, A Cowppli-Bony, S Ayrault-Piault, E Fournier, AS Woronoff, C Delpierre, and P Grosclaude. Using ecological  
1070 socioeconomic position (sep) measures to deal with sample bias introduced by incomplete individual-level measures: inequalities in breast cancer  
1071 stage at diagnosis as an example. *BMC PUBLIC HEALTH*, 19, 7 2019.
- 1072 [82] Bruce E. Landon, Jukka-Pekka Onnela, Laurie Meneades, A. James O'Malley, and Nancy L. Keating. Assessment of racial disparities in primary  
1073 care physician specialty referrals. *JAMA network open*, 4(1):e2029238, 1 2021. PMID: 33492373 PMID: PMC7835717.
- 1074 [83] D. R. Lannin, H. F. Mathews, J. Mitchell, M. S. Swanson, F. H. Swanson, and M. S. Edwards. Influence of socioeconomic and cultural factors on  
1075 racial differences in late-stage presentation of breast cancer. *JAMA*, 279(22):1801–1807, 6 1998. PMID: 9628711.
- 1076 [84] AJ Larrazabal, N Nieto, V Peterson, DH Milone, and E Ferrante. Gender imbalance in medical imaging datasets produces biased classifiers for  
1077 computer-aided diagnosis. *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*, 117(23):12592–12594,  
1078 6 2020.
- 1079 [85] O Lediju, J Ikuemonisan, SS Salami, and O Adejoro. Racial disparities in the presentation, early definitive surgical treatment, and mortality among  
1080 men diagnosed with poorly differentiated/undifferentiated non-metastatic prostate cancer in the usa. *JOURNAL OF RACIAL AND ETHNIC HEALTH  
1081 DISPARITIES*, 6(2):401–408, 4 2019.
- 1082 [86] Ian Litchfield, Naiem Moiemen, and Sheila Greenfield. Barriers to evidence-based treatment of serious burns: The impact of implicit bias on  
1083 clinician perceptions of patient adherence. *Journal of burn care research : official publication of the American Burn Association*, 41(6):1297–1300, 11  
1084 2020. publisher-place: England PMID: 32645716.
- 1085 [87] Jonathan M. Loree, Seerat Anand, Arvind Dasari, Joseph M. Unger, Anirudh Gothwal, Lee M. Ellis, Gauri Varadhachary, Scott Kopetz, Michael J.  
1086 Overman, and Kanwal Raghav. Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018.  
1087 *JAMA Oncology*, 5(10):e191870, 10 2019.
- 1088 [88] Z Kevin Lu, Xiaomo Xiong, Xinyuan Wang, and Jun Wu. Gender disparities in anti-dementia medication use among older adults: Health equity  
1089 considerations and management of alzheimer's disease and related dementias. *Frontiers in Pharmacology*, 12:706762, 2021.
- 1090 [89] Y Luo, H Carretta, I Lee, G LeBlanc, D Sinha, and G Rust. Naive bayesian network-based contribution analysis of tumor biology and healthcare  
1091 factors to racial disparity in breast cancer stage-at-diagnosis. *HEALTH INFORMATION SCIENCE AND SYSTEMS*, 9(1), 9 2021.
- 1092 [90] J Lv, L Ni, KX Liu, XJ Gao, JG Yang, X Zhang, YQ Ye, QT Dong, R Fu, H Sun, XX Yan, YY Zhao, Y Wang, YJ Yang, and HY Xu. Clinical characteristics,  
1093 prognosis, and gender disparities in young patients with acute myocardial infarction. *FRONTIERS IN CARDIOVASCULAR MEDICINE*, 8, 8 2021.
- 1094 [91] R Mallick, RB Xie, JK Kirklín, H Chen, and CJ Balentine. Race and gender disparities in access to parathyroidectomy: A need to change processes  
1095 for diagnosis and referral to surgeons. *ANNALS OF SURGICAL ONCOLOGY*, 28(1):476–483, 1 2021.

- 1093 [92] K. McCaffery, J. Wardle, M. Nadel, and W. Atkin. Socioeconomic variation in participation in colorectal cancer screening. *Journal of Medical*  
1094 *Screening*, 9(3):104–108, 2002. PMID: 12370320.
- 1095 [93] UC Megwalu and YF Ma. Racial disparities in oropharyngeal cancer stage at diagnosis. *ANTICANCER RESEARCH*, 37(2):835–839, 2 2017.
- 1096 [94] UC Megwalu and YF Ma. Racial/ethnic disparities in use of high-quality hospitals among thyroid cancer patients. *CANCER INVESTIGATION*,  
1097 39(6-7):482–488, 8 2021.
- 1098 [95] Rajendra H. Mehta, David M. Shahian, Shubin Sheng, Sean M. O’Brien, Fred H. Edwards, Jeffery P. Jacobs, and Eric D. Peterson. Association of  
1099 hospital and physician characteristics and care processes with racial disparities in procedural outcomes among contemporary patients undergoing  
1100 coronary artery bypass grafting surgery. *Circulation*, 133(2):124–130, 1 2016. publisher-place: United States PMID: 26603032.
- 1101 [96] Chloe Mirzayi, Audrey Renson, Genomic Standards Consortium, Massive Analysis, Quality Control Society Furlanello Cesare 31 Sansone Susanna-  
1102 Assunta 84, Fatima Zohra, Shaimaa Elsafoury, Ludwig Geistlinger, Lora J Kasselmann, Kelly Eckenrode, Janneke van de Wijgert, et al. Reporting  
1103 guidelines for human microbiome research: the storms checklist. *Nature medicine*, 27(11):1885–1892, 2021.
- 1104 [97] RL Morgan, SD Karam, and CJ Bradley. Ethnic disparities in imaging utilization at diagnosis of non-small cell lung cancer. *JNCI-JOURNAL OF THE*  
1105 *NATIONAL CANCER INSTITUTE*, 112(12):1204–1212, 12 2020.
- 1106 [98] Jessica Morley, Caio CV Machado, Christopher Burr, Josh Cows, Indra Joshi, Mariarosaria Taddeo, and Luciano Floridi. The ethics of ai in health  
1107 care: a mapping review. *Social Science & Medicine*, 260:113172, 2020.
- 1108 [99] N Morshed and FB Zhan. Racial/ethnic, social characteristics and geographic disparities of childhood cancer late-stage diagnosis in texas, 2005 to  
1109 2014. *ANNALS OF GIS*, 27(4):329–340, 2021.
- 1110 [100] A Mukherjee, AJ Idigo, YF Ye, HW Wiener, R Paluri, LM Nabell, and S Shrestha. Geographical and racial disparities in head and neck cancer  
1111 diagnosis in south-eastern united states: Using real-world electronic medical records data. *HEALTH EQUITY*, 4(1):43–51, 2020.
- 1112 [101] Sendhil Mullainathan and Ziad Obermeyer. Diagnosing physician error: A machine learning approach to low-value health care. *The Quarterly*  
1113 *Journal of Economics*, 137(2):679–727, 2022.
- 1114 [102] Keisuke Nakagawa, Lama Moukheiber, Leo A Celi, Malhar Patel, Faisal Mahmood, Dibson Gondim, Michael Hogarth, and Richard Levenson. Ai in  
1115 pathology: what could possibly go wrong? In *Seminars in Diagnostic Pathology*, volume 40, pages 100–108. Elsevier, 2023.
- 1116 [103] Sophia R Newcomer, Stan Xu, Martin Kulldorff, Matthew F Daley, Bruce Fireman, and Jason M Glanz. A primer on quantitative bias analysis with  
1117 positive predictive values in research using electronic health data. *Journal of the American Medical Informatics Association*, 26(12):1664–1674, 2019.
- 1118 [104] C Niederwanger, T Varga, T Hell, D Stuerzel, J Prem, M Gassner, F Rickmann, C Schoner, D Hainz, G Cortina, B Hetzer, B Treml, and M Bachler.  
1119 Comparison of pediatric scoring systems for mortality in septic patients and the impact of missing information on their predictive power: a  
1120 retrospective analysis. *PEERJ*, 8, 10 2020.
- 1121 [105] Ziad Obermeyer, Brian Powers, Christine Vogeli, and Sendhil Mullainathan. Dissecting racial bias in an algorithm used to manage the health of  
1122 populations. *Science*, 366(6464):447–453, 2019.
- 1123 [106] OE Okunlola, MS Lipnick, PB Batchelder, M Bernstein, JR Feiner, and PE Bickler. Pulse oximeter performance, racial inequity, and the work ahead.  
1124 *RESPIRATORY CARE*, 67(2):252–257, 2 2022.
- 1125 [107] J Omorodion, L Dowsett, RD Clark, J Fraser, A Abu-El-Haija, A Strong, MH Wojcik, AS Bryant, and NB Gold. Delayed diagnosis and racial bias in  
1126 children with genetic conditions. *AMERICAN JOURNAL OF MEDICAL GENETICS PART A*, 188(4):1118–1123, 4 2022.
- 1127 [108] Alan G. Palestine, Pauline T. Merrill, Sophia M. Saleem, Douglas A. Jabs, and Jennifer E. Thorne. Assessing the precision of icd-10 codes for uveitis  
1128 in 2 electronic health record systems. *JAMA ophthalmology*, 136(10):1186–1190, 10 2018. PMID: 30054618 PMID: PMC6583860.
- 1129 [109] Parita Patel, Charles Muller, and Sonali Paul. Racial disparities in nonalcoholic fatty liver disease clinical trial enrollment: A systematic review and  
1130 meta-analysis. *World Journal of Hepatology*, 12(8):506–518, 8 2020. PMID: 32952877 PMID: PMC7475777.
- 1131 [110] Louis A. Penner, John F. Dovidio, Richard Gonzalez, Terrance L. Albrecht, Robert Chapman, Tanina Foster, Felicity W. K. Harper, Nao Hagiwara,  
1132 Lauren M. Hamel, Anthony F. Shields, Shirish Gadgeel, Michael S. Simon, Jennifer J. Griggs, and Susan Eggly. The effects of oncologist implicit  
1133 racial bias in racially discordant oncology interactions. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*,  
34(24):2874–2880, 8 2016. PMID: 27325865 PMID: PMC5012663.
- 1134 [111] Oriël Perets and Nadav Rappoport. Ensemble synthetic ehr generation for increasing subpopulation model’s performance. *arXiv preprint*  
1135 *arXiv:2305.16363*, 2023.
- 1136 [112] Susan E Puumala, Katherine M Burgess, Anupam B Kharbanda, Heather G Zook, Dorothy M Castille, Wyatt J Pickner, and Nathaniel R Payne. The  
1137 role of bias by emergency department providers in care for american indian children. *Medical care*, 54(6):562–569, 2016.
- 1138 [113] K Reinard, DR Nerenz, A Basheer, R Tahir, T Jelsema, L Schultz, G Malik, EL Air, and JM Schwalb. Racial disparities in the diagnosis and management  
1139 of trigeminal neuralgia. *JOURNAL OF NEUROSURGERY*, 126(2):368–374, 2 2017.
- 1140 [114] David Robertson and Gordon H Williams. *Clinical and translational science: principles of human research*. Academic Press, 2009.
- 1141 [115] CA Samuel-Ryals, OM Mbah, SP Hinton, SH Cross, BB Reeve, and SB Dusetzina. Evaluating the contribution of patient-provider communication  
1142 and cancer diagnosis to racial disparities in end-of-life care among medicare beneficiaries. *JOURNAL OF GENERAL INTERNAL MEDICINE*,  
36(11):3311–3320, 11 2021.
- 1143 [116] O Sartor, MJ Morris, and BJ Kraus. Racial bias in pulse oximetry measurement (vol 383, pg 2477, 2020). *NEW ENGLAND JOURNAL OF MEDICINE*,  
385(26):2496–2496, 12 2021.
- 1144 [117] DM Schiff, T Nielsen, BB Hoepfner, M Terplan, H Hansen, D Bernson, H Diop, M Bharel, EE Krans, S Selk, JF Kelly, TE Wilens, and EM Taveras.  
Assessment of racial and ethnic disparities in the use of medication to treat opioid use disorder among pregnant women in massachusetts. *JAMA*
- Manuscript submitted to ACM

- 1145 NETWORK OPEN, 3(5), 5 2020.
- 1146 [118] Andi Shahu, Jeph Herrin, Sanket S. Dhruva, Nihar R. Desai, Barry R. Davis, Harlan M. Krumholz, and Erica S. Spatz. Disparities in socioeconomic  
1147 context and association with blood pressure control and cardiovascular outcomes in allhat. *Journal of the American Heart Association*, 8(15):e012277,  
1148 8 2019. PMID: 31362591 PMCID: PMC6761647.
- 1149 [119] E Shimron, JI Tamir, K Wang, and M Lustig. Implicit data crimes: Machine learning bias arising from misuse of public data. *PROCEEDINGS OF THE  
1150 NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*, 119(13), 3 2022.
- 1151 [120] Haytham Siala and Yichuan Wang. Shifting artificial intelligence to be responsible in healthcare: A systematic review. *Social Science & Medicine*,  
1152 296:114782, 2022.
- 1153 [121] Omar Sims, David Pollio, Barry Hong, and Carol North. Racial disparities in hepatitis c treatment eligibility. *Annals of hepatology*, 16(4):530–537, 8  
1154 2017. publisher-place: Mexico PMID: 28611273.
- 1155 [122] Sachil Singh. Racial biases in healthcare: Examining the contributions of point of care tools and unintended practitioner bias to patient treatment  
1156 and diagnosis. *Health*, 27(5):829–846, 2023.
- 1157 [123] Emily A. Slopnick, Simon P. Kim, Jonathan E. Kiechle, Christopher M. Gonzalez, Hui Zhu, and Robert Abouassaly. Racial disparities differ for  
1158 african americans and hispanics in the diagnosis and treatment of penile cancer. *Urology*, 96:22–28, 10 2016. publisher-place: United States PMID:  
1159 27402373.
- 1160 [124] "Statista". Healthcare data storage constraints globally 2020 forecast | statista. [Online; accessed 2023-06-21].
- 1161 [125] AE Stenzel, RA Fenstermaker, LM Wiltsie, and KB Moysich. Disparities among racial/ethnic groups of patients diagnosed with ependymoma:  
1162 analyses from the surveillance, epidemiology and end results (seer) registry. *JOURNAL OF NEURO-ONCOLOGY*, 144(1):43–51, 8 2019.
- 1163 [126] MW Sullivan, FT Camacho, AM Mills, and SC Modesitt. Missing information in statewide and national cancer databases: Correlation with health  
1164 risk factors, geographic disparities, and outcomes. *GYNECOLOGIC ONCOLOGY*, 152(1):119–126, 1 2019.
- 1165 [127] Martin J. Tobin and Amal Jubran. Pulse oximetry, racial bias and statistical bias. *Annals of intensive care*, 12(1):2, 1 2022. PMID: 34981267 PMCID:  
1166 PMC8723900.
- 1167 [128] Nenad Tomašev, Xavier Glorot, Jack W. Rae, Michal Zielinski, Harry Askham, Andre Saraiva, Anne Mottram, Clemens Meyer, Suman Ravuri, Ivan  
1168 Protsyuk, Alistair Connell, Cian O. Hughes, Alan Karthikesalingam, Julien Cornebise, Hugh Montgomery, Geraint Rees, Chris Laing, Clifton R.  
1169 Baker, Kelly Peterson, Ruth Reeves, Demis Hassabis, Dominic King, Mustafa Suleyman, Trevor Back, Christopher Nielson, Joseph R. Ledsam, and  
1170 Shakir Mohamed. A clinically applicable approach to continuous prediction of future acute kidney injury. *Nature*, 572(7767):116–119, 8 2019.  
1171 number: 7767 publisher: Nature Publishing Group.
- 1172 [129] Andrea C Tricco, Erin Lillie, Wasifa Zarin, Kelly K O'Brien, Heather Colquhoun, Danielle Levac, David Moher, Micah DJ Peters, Tanya Horsley,  
1173 Laura Weeks, et al. Prisma extension for scoping reviews (prisma-scr): checklist and explanation. *Annals of internal medicine*, 169(7):467–473, 2018.
- 1174 [130] Jessica W. Tsai and Jennifer C. Kesselheim. Addressing implicit bias in pediatric hematology-oncology. *Pediatric blood cancer*, 67(5):e28204, 5 2020.  
1175 publisher-place: United States PMID: 32159300.
- 1176 [131] E Tsou, RE Kiekhof, EL Guterman, BL Tee, CC Windon, KA Dorsman, SC Lanata, GD Rabinovici, BL Miller, AJH Kind, and KL Possin. Assessment  
1177 of racial/ethnic disparities in timeliness and comprehensiveness of dementia diagnosis in california. *JAMA NEUROLOGY*, 78(6):657–665, 6 2021.
- 1178 [132] S Udoetuk, D Dongarwar, and HM Salihu. Racial and gender disparities in diagnosis of malingering in clinical settings. *JOURNAL OF RACIAL  
1179 AND ETHNIC HEALTH DISPARITIES*, 7(6):1117–1123, 12 2020.
- 1180 [133] Valeria S. M. Valbuena, Ryan P. Barbaro, Dru Claar, Thomas S. Valley, Robert P. Dickson, Steven E. Gay, Michael W. Sjoding, and Theodore J.  
1181 Iwashyna. Racial bias in pulse oximetry measurement among patients about to undergo extracorporeal membrane oxygenation in 2019–2020: A  
1182 retrospective cohort study. *Chest*, 161(4):971–978, 4 2022. PMID: 34592317 PMCID: PMC9005857.
- 1183 [134] Michelle Van Ryn and Jane Burke. The effect of patient race and socio-economic status on physicians' perceptions of patients. *Social science &  
1184 medicine*, 50(6):813–828, 2000.
- 1185 [135] K Wallace, H Li, CM Paulos, DN Lewin, and AV Alekseyenko. Racial disparity in survival of patients diagnosed with early-onset colorectal cancer.  
1186 *COLORECTAL CANCER*, 9(3), 10 2020.
- 1187 [136] F Wang, W Zheng, CE Bailey, IA Mayer, JA Pietenpol, and XO Shu. Racial/ethnic disparities in all-cause mortality among patients diagnosed with  
1188 triple-negative breast cancer. *CANCER RESEARCH*, 81(4):1163–1170, 2 2021.
- 1189 [137] Xiaoyan Wang, Derek S Brown, Yin Cao, Christine C Ekenka, Shenyang Guo, and Kimberly J Johnson. The impact of health insurance coverage on  
1190 racial/ethnic disparities in us childhood and adolescent cancer stage at diagnosis. *Cancer*, 128(17):3196–3203, 2022.
- 1191 [138] JL Wiltz. Racial and ethnic disparities in receipt of medications for treatment of covid-19 - united states, march 2020-august 2021 (vol 71, pg 96,  
1192 2022). *MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT*, 71(8):325–325, 2 2022.
- 1193 [139] Julie A Wolfson, Can-Lan Sun, Laura P Wyatt, Arti Hurria, and Smita Bhatia. Impact of care at comprehensive cancer centers on outcome: results  
1194 from a population-based study. *Cancer*, 121(21):3885–3893, 2015.
- 1195 [140] An-Kwok Ian Wong, Marie Charpignon, Han Kim, Christopher Josef, Anne AH De Hond, Jhalique Jane Fojas, Azade Tabaei, Xiaoli Liu, Eduardo  
1196 Mireles-Cabodevila, Leandro Carvalho, et al. Analysis of discrepancies between pulse oximetry and arterial oxygen saturation measurements by  
1197 race and ethnicity and association with organ dysfunction and mortality. *JAMA Network Open*, 4(11):e2131674–e2131674, 2021.
- 1198 [141] Evan S. Wu, Jong Y. Park, Joseph A. Zeitouni, Carmen R. Gomez, Isildinha M. Reis, Wei Zhao, Deukwoo Kwon, Eunkyung Lee, Omar L. Nelson,  
1199 Hui-Yi Lin, Elizabeth J. Franzmann, Jason Savell, Thomas V. McCaffrey, W. Jarrard Goodwin, and Jennifer J. Hu. Effect of actionable somatic  
1200 mutations on racial/ethnic disparities in head and neck cancer prognosis. *Head neck*, 38(8):1234–1241, 8 2016. publisher-place: United States

24

1197 PMID: 27028310.

1198 [142] GY Wu, J Wu, XB Pan, B Liu, ZC Yao, Y Guo, XL Shi, and YT Ding. Racial disparities in alpha-fetoprotein testing and alpha-fetoprotein status  
1199 associated with the diagnosis and outcome of hepatocellular carcinoma patients. *CANCER MEDICINE*, 8(15):6614–6623, 11 2019.

1200 [143] Haifeng Xu, Jianfei Pang, Weiliang Zhang, Xuemeng Li, Mei Li, and Dongsheng Zhao. Predicting recurrence for patients with ischemic  
1201 cerebrovascular events based on process discovery and transfer learning. *IEEE Journal of Biomedical and Health Informatics*, 25(7):2445–2453, 7  
1202 2021. event-title: IEEE Journal of Biomedical and Health Informatics.

1203 [144] Kun-Hsing Yu, Andrew L Beam, and Isaac S Kohane. Artificial intelligence in healthcare. *Nature biomedical engineering*, 2(10):719–731, 2018.

1204 [145] Carolyn W Zhu, Judith Neugroschl, Lisa L Barnes, and Mary Sano. Racial/ethnic disparities in initiation and persistent use of anti-dementia  
1205 medications. *Alzheimer's & Dementia*, 18(12):2582–2592, 2022.

1206 Received 20 February 2024

1207

1208

1209

1210

1211

1212

1213

1214

1215

1216

1217

1218

1219

1220

1221

1222

1223

1224

1225

1226

1227

1228

1229

1230

1231

1232

1233

1234

1235

1236

1237

1238

1239

1240

1241

1242

1243

1244

1245

1246

1247

1248

Manuscript submitted to ACM



Identification

Studies from databases/registers (n = 410)

References from other sources (n = 20)  
 Citation searching (n = 18)  
 Grey literature (n = 0)

References removed (n = 27)  
 Duplicates identified manually (n = )  
 Duplicates identified by Covidence (n = )  
 Marked as ineligible by automation tools (n = )  
 Other reasons (n = )

Screening

Studies screened (n = 403)

Studies excluded (n = 191)

Studies sought for retrieval (n = 212)

Studies not retrieved (n = 0)

Studies assessed for eligibility (n = 212)

Studies excluded (n = 96)  
 No full text (n = 1)  
 No inherit bias (n = 24)  
 Irrelevant topic (n = 6)  
 Inappropriate study design (n = 15)  
 Not electronic health records (n = 5)  
 Showing prevalence and not bias (n = 45)

Included

Studies included in review (n = 116)

